If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-10. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
This process can also be further adjusted by manipulating factors such as pH, temperature, exudate dilution and plant origin to produce different shapes of nanoparticles, including triangles, spheres, rods, and spirals. These biogenic metallic nanoparticles then have applications as catalysts, glass window coatings to insulate heat, in biomedicine, and in biosensor devices.
Environmental scientists use ecosystem monitoring in the field to gather reliable data with minimal disturbance. In medicine, especially oncology, carcinoma in situ describes early-stage cancers that remain localized at their site of origin. Space exploration relies on in situ methods to conduct direct observational studies and data collection on celestial bodies, avoiding the challenges of sample-return missions. In archaeology, in situ generally refers to artifacts and features found in undisturbed depositional settings, where recording spatial and stratigraphic relationships preserves information about past human activities. In art, in situ refers to works created or displayed in dialogue with their surroundings: site-specific projects, such as environmental sculptures or architectural installations, are conceived for particular locations.
== History == SCIEX was founded in 1974 by Canadian scientists Barry French, Neil Reid, Adele Buckley, and businessman William Breukelman, to develop a mass spectrometer system based on atmospheric pressure ionisation and direct air sampling. In 1981, SCIEX was acquired by MDS Inc., a Canadian medical services and equipment company. A joint venture was formed with PerkinElmer for sales and marketing of the inductively coupled plasma mass spectrometry (ICPMS) product line. In 1986, the joint venture was extended to include the liquid chromatography–mass spectrometry (LC/MS) business, managed through the Applied Biosystems division of Perkin Elmer. In 2008, Applied Biosystems merged with Invitrogen to form Life Technologies. In 2009, Danaher Corporation paid approximately $1.1 billion to buy SCIEX from MDS and the Applied Biosystems/MDS SCIEX joint venture business from Life Technologies. The business unit now operates as SCIEX within the Life Sciences Division of Danaher and is one of the major players in the global mass spectrometry market estimated (in 2018) at $5.5 billion worldwide.
A fully oxygenated orthorhombic YBa2Cu3O7−x sample can be transformed into tetragonal YBa2Cu3O6 by heating in a vacuum at temperature above 973 K (700 °C). The preparation of Bi-, Tl- and Hg-based high-Tc superconductors is more difficult than the YBCO preparation. Problems in these superconductors arise because of the existence of three or more phases having a similar layered structure. Thus, syntactic intergrowth and defects such as stacking faults occur during synthesis and it becomes difficult to isolate a single superconducting phase. For Bi–Sr–Ca–Cu–O, it is relatively simple to prepare the Bi-2212 (Tc ≈ 85 K) phase, whereas it is very difficult to prepare a single phase of Bi-2223 (Tc ≈ 110 K). The Bi-2212 phase appears only after few hours of sintering at 1,130–1,140 K (860–870 °C), but the larger fraction of the Bi-2223 phase is formed after a long reaction time of more than a week at 1,140 K (870 °C). Although the substitution of Pb in the Bi–Sr–Ca–Cu–O compound has been found to promote the growth of the high-Tc phase, a long sintering time is still required.
In the United States, the term "nickel" or "nick" originally applied to the copper-nickel Flying Eagle cent, which replaced copper with 12% nickel 1857–58, then the Indian Head cent of the same alloy from 1859 to 1864. Still later, in 1865, the term designated the three-cent nickel, with nickel increased to 25%. In 1866, the five-cent shield nickel (25% nickel, 75% copper) appropriated the designation, which has been used ever since for the subsequent 5-cent pieces. This alloy proportion is not ferromagnetic. The US nickel coin contains 0.04 ounces (1.1 g) of nickel, which at the April 2007 price was worth 6.5 cents, along with 3.75 grams of copper worth about 3 cents, with a total metal value of more than 9 cents. Since the face value of a nickel is 5 cents, this made it an attractive target for melting by people wanting to sell the metals at a profit. The United States Mint, anticipating this practice, implemented new interim rules on December 14, 2006, subject to public comment for 30 days, which criminalized the melting and export of cents and nickels. Violators can be punished with a fine of up to $10,000 and/or a maximum of five years in prison. As of February 19, 2025, the melt value of a US nickel (copper and nickel included) is $0.054 (108% of the face value).
Sources: en.wikipedia.org
=== Venoms === Certain types of venom, such as those produced by venomous snakes, can also cause proteolysis. These venoms are, in fact, complex digestive fluids that begin their work outside of the body. Proteolytic venoms cause a wide range of toxic effects, including effects that are:
== Recreational use == In 1979, the first case of xylazine toxicity was reported in a 34-year-old male who had self-medicated for insomnia with an injection of 1g of xylazine. In the US, Xylazine is not regulated as a controlled substance under the Controlled Substances Act. It is sold online through distributors often without requiring proof of a veterinary license. The cost to purchase Xylazine from overseas suppliers is around $6–20 per kilogram. This low price makes it attractive for dealers looking for a cheap additive that is addictive and not treatable with opiate withdrawal medications. The withdrawal can last for two weeks and has a quicker onset than fentanyl. As an adulterant, xylazine is most commonly ingested with fentanyl. Xylazine has also been reported in combination with medetomidine, another potent α2-adrenergic receptor agonist. It is unknown if drug users are ingesting it knowingly. As of 2024, Seattle police report that some users wrongly believe they are consuming higher-quality fentanyl. Xylazine's street name in Puerto Rico is anestesia de caballo, which translates to "horse anesthetic". From 2002 to 2008, its use was associated with a high number of inmate deaths at the Guerrero Correctional Institution in Aguadilla, Puerto Rico. Xylazine's street name in the United States, particularly when it is mixed with fentanyl, is "tranq", "tranq dope" and "zombie drug". As of 2012, xylazine users in Puerto Rico were more likely to be male, under age 30, living in a rural area, and injecting rather than inhaling xylazine.
Complement component 1s (EC 3.4.21.42, C1 esterase, activated complement C1s, complement C overbar 1r, C1s) is a protein involved in the complement system. C1s is part of the C1 complex. In humans, it is encoded by the C1S gene. C1s cleaves C4 and C2, which eventually leads to the production of the classical pathway C3-convertase.
According to Pio Smith, UNFPA’s Asia-Pacific regional director, the USAID freeze could lead to 1,200 maternal deaths and 109,000 additional unwanted pregnancies in the next three years in Afghanistan. A USAID info memo written by Nicholas Enrich, Acting Assistant Administrator for Global Health, dated March 4, 2025, outlined the risks of the aid freeze. He stated that a permanent suspension of lifesaving humanitarian aid posed a direct threat to public health, economic stability, national security and biothreat vulnerability. He concluded: "Any decision to halt or significantly reduce global health funding for lifesaving humanitarian assistance (LHA)—despite approved waivers—and USAID global health programming, despite congressional mandates, would have severe domestic and global consequences." Enrich was notified that he was put on administrative leave less than 30 minutes after the memo's publication, a decision that had reportedly been made a week prior. Pe Kha Lau, 71, died after she was discharged from a USAID-funded healthcare facility operated by the International Rescue Committee (IRC) while still relying on oxygen to survive. In the Umpiem Mai camp in Thailand, witnesses reported the deaths of multiple patients who too relied on oxygen. The IRC offered their condolences to the family and friends of Pe Kha Lau. Nicholas Kristof also documented evidence contradicting Elon Musk's claim that "No one has died as a result of a brief pause to do a sanity check on foreign aid funding.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.